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Abstract 
Several studies suggest that cyclooxygenase-2 contributes to the delayed progression of ischemic brain 
damage. In this study we examined whether the highly selective cyclooxygenase-2 inhibitor DFU 
reduces neuronal damage when administered several hours after 5 min of transient forebrain ischemia 
in gerbils. The extent of ischemic injury was assessed behaviorally by measuring the increases in 
locomotor activity and by histopathological evaluation of the extent of CA1 hippocampal pyramidal 
cell injury 7 days after ischemia. DFU treatment (10 mg/kg, p.o.) significantly reduced hippocampal 
neuronal damage even if the treatment is delayed until 12 h after ischemia. These results suggest that 
selective cyclooxygenase-2 inhibitors may be a valuable therapeutic strategy for ischemic brain injury. 
 
 
Theme: Disorders of the nervous system 
Topic: Ischemia 
Key words: cyclooxygenase-2; cerebral ischemia; neuroprotection; hippocampus; gerbil; DFU 
 
Candelario-Jalil et al., 2002                                                           Brain Res. 927(2): 212-155 (2002) 
 
 
Brain damage accompanying cardiac arrest and resuscitation is frequent and devastating [24]. The 
cornu Ammonis 1 (CA1) neurons of the hippocampus are widely regarded as among the most 
vulnerable in the mammalian CNS to ischemia [11,12,20]. Detailed analysis on the time course of 
selective loss of pyramidal cells in CA1 hippocampal sector showed that the neuronal death is a slow 
process taking 2-3 days before presenting the final morphologic outcome [11,20], suggesting that 
mechanisms that develop after ischemia have an important role in ischemic neuronal demise. The 
delayed degeneration of neurons provides the opportunity for neuroprotective agents to be 
administered following the ischemic insult. 
 
There is mounting evidence that post-ischemic cyclooxygenase-2 induction contributes to ischemic 
brain damage [9,18,19]. It has been known for decades that cyclooxygenase inhibitors decrease 
ischemic brain injury [17,22]. Recently, it has been reported that cyclooxygenase-2 selective inhibitors 
prevent both post-ischemic prostaglandin accumulation and ischemic neuronal damage [18,19], 
suggesting that the beneficial effects observed with non-selective cyclooxygenase inhibitors are 
probably associated to cyclooxygenase-2 rather than to cyclooxygenase-1 inhibition.  
 
Induction of cyclooxygenase-2 mRNA and protein through activation of AMPA receptors in global 
ischemia suggests that cyclooxygenase-2 is a mediator of glutamate excitotoxicity [13]. While several 
genes are induced in the susceptible CA1 neurons after global ischemia, very few reach expression at 
the protein level [14]. The induced cyclooxygenase-2 mRNA is translated to protein in models of 
global cerebral ischemia [13,18]. Cyclooxygenase-2 is one of a select few proteins that still remains 
upregulated in CA1 pyramidal cells even at 3 days after the ischemic insult [13,18], thus preceding the 
death of these neurons. 
 
In the present study, we examined whether a highly selective cyclooxygenase-2 inhibitor reduces 
neuronal damage in the gerbil hippocampus when administered several hours after transient global 
ischemia.  
 
Male Mongolian gerbils (Meriones unguiculatus; 60-75 g) were anesthetized with chloral hydrate (300 
mg/kg, i.p.) and subjected to both common carotid arteries occlusion for 5 min, exactly as in our 
previous work [4]. Rectal temperature was monitored and maintained at 37 ± 0.5 °C. In addition, rectal 
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temperature was carefully monitored at 8-h intervals for 3 days of reperfusion. In sham-operated group 
(n=5), the arteries were freed from connective tissue but were not occluded. 
 
The novel orally active and highly selective cyclooxygenase-2 inhibitor DFU (5,5-dimethyl-3-(3-
fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanone) (Merck Frosst, Quebec, Canada) was 
administered orally (10 mg/kg) 30 min before ischemia and again at 6, 12, 24, 48 and 72 h of 
reperfusion (n=6). In other groups, DFU was dosed 6 (n=9) and 12 h (n=9) after induction of ischemia, 
followed by additional single oral doses at 24, 48 and 72 h. This treatment schedule was based on 
previous reports showing a persistent cyclooxygenase-2 protein expression in CA1 neurons after 
global ischemia [13,18]. The dose of DFU used in the study was based on a previous work showing 
maximal antiinflammatory effect [21]. In the ischemic control group (n=7) the animals were treated 
orally with vehicle (1% methocel) for 3 days.  
 
All animals were tested for spontaneous locomotor activity in an automated activity meter (Model 
7401, Ugo Basile, Varese, Italy). Each individual gerbil was monitored for a 30 min period after a 10 
min interval for adaptation. Locomotor activity was measured prior to, and 7 days after the ischemic 
episode. This behavioral test has been previously shown to accurately predict the degree of ischemia-
induced hippocampal damage [1].  
 
Following the final motor activity session on the seventh day post-ischemia, the animals were 
anesthetized with urethane and perfused transcardially with cold saline followed by 4% 
paraformaldehyde in phosphate-buffered saline (pH 7.4). The brains were removed from the skull and 
fixed in the same fixative for 24 h. Thereafter, the brains were embedded in paraffin and representative 
coronal sections (5-μm thick), which included the dorsal hippocampus, were obtained with a rotary 
microtome. Tissue sections were stained with hematoxylin and eosin. The hippocampal damage was 
determined by counting the number of intact neurons in the striatum pyramidale within the CA1 
subfield at a magnification of 40x [15]. Only neurons with normal visible nuclei were counted. The 
mean number of CA1 neurons per mm linear length for both hemispheres in three adjacent sections of 
dorsal hippocampus was calculated for each group of animals. All assessments of histological sections 
were made by an observer who was unaware of the drug treatment for each gerbil. The data was 
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expressed as a mean value ± SD. Statistical analysis was performed using ANOVA followed by 
Student-Newman-Keuls post-hoc test and significance refers to results where p<0.05 was obtained. 
 
After 7 days of bilateral carotid occlusion for 5 min, the vehicle-treated ischemic gerbils displayed a 
characteristic significant increase in locomotor activity with respect to both their own pre-ischemia 
basal level and the sham group (Table 1).  Seven days post-ischemia, all the gerbils which received 
DFU (10 mg/kg, p.o.) showed a significant reduction (p<0.05) in locomotor activity as compared to 
vehicle-treated group (Table 1).  
 
Histologic examination of the brain demonstrated marked cell damage in the hippocampal CA1 region 
in the gerbils treated with vehicle when compared with the sham-operated group. CA1 pyramidal 
neurons showed pyknosis, eosinophilia, karyorrhexis and chromatin condensation in ischemic gerbils. 
Figure 1 shows that by 7 days after ischemia, there is a 76% loss of medial CA1 neurons in the 
vehicle-treated animals (sham = 223 ± 13; vehicle = 55 ± 12 neurons/mm). Administration of the 
highly cyclooxygenase-2 inhibitor DFU significantly (p<0.05) reduced neuronal damage induced by 
global ischemia when administered 30 min prior to the 5 min period of carotid occlusion (vehicle = 55 
± 12 vs DFU pre-ischemia = 170 ± 16 neurons/mm; Fig 1). We tried to determine whether a 
cyclooxygenase-2 inhibitor could protect neurons when applied several hours after ischemia. For this 
purpose we administered DFU 6 and 12 h after the insult. All application schedules led to statistically 
significant increase in healthy neurons in the CA1 layer (p<0.05) as shown in Fig. 1. Of special 
interest is the finding that when DFU treatment is delayed until 6 h after ischemia the neuroprotection 
is comparable to that seen in the group in which DFU treatment began before ischemia (Fig 1). The 
protective effects of this cyclooxygenase-2 inhibitor are also seen if administrated 12 h after ischemia 
(Fig. 1). The protection conferred by DFU is not attributable to effects on body temperature because 
this variable was monitored and did not differ between treated and un-treated groups (data not shown). 
 
The reduction in locomotor activity in DFU-treated groups correlated well with the histopathological 
evidence of protection against hippocampal damage after ischemia (Table 1 and Fig. 1). 
 
To our knowledge, there is no previous study on the neuroprotective effects of a highly selective 
cyclooxygenase-2 inhibitor against brain injury induced by global ischemia showing this wide 
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therapeutic window of protection. The present results suggest that cyclooxygenase-2 plays an 
important role in the deleterious cascade of molecular events which leads to neuronal damage of CA1 
pyramidal cells after transient global ischemia. 
 
Cyclooxygenase-2 inhibitors have been previously shown to decrease infarct size in rats after transient 
middle cerebral artery occlusion [19], to prevent delayed death of CA1 neurons following 30 min of 
global ischemia in rats [18], to attenuate white matter damage in chronic cerebral ischemia [23] and to 
reduce ischemic photothrombotic brain injury in rats [6]. The present study confirms the ability of 
highly selective cyclooxygenase-2 inhibitors to decrease selective vulnerability of CA1 hippocampal 
neurons and shows that this effect is present even when treatment begins several hours after ischemia. 
The observation that DFU is protective in ischemic brain injury in gerbils, suggests that the 
neuroprotective effects of cyclooxygenase-2 inhibitors are maintained across species.  
 
Although the factors responsible for the cytotoxicity of cyclooxygenase-2 in cerebral injury induced 
by ischemia remain to be clearly defined, it is likely that one of the mechanisms is related to 
production of reactive oxygen species [16]. In line with this notion, we have recently found that a 
cyclooxygenase-2 inhibitor is able to reduce hippocampal oxidative damage following excitotoxic 
brain injury [3], which is a key pathological event of cerebral ischemia. Cyclooxygenase-2 enzymatic 
activity can also mediate tissue damage by producing pro-inflammatory prostanoids [16]. 
Interestingly, prostaglandins stimulates calcium-dependent glutamate release in astrocytes [2], thus 
contributing to excitotoxicity. However, the precise role of prostaglandins in neurotoxicity is 
controversial because prostaglandin E2 has also been reported to limit the cytotoxic effects of 
glutamate [5].  
 
On the other hand, pharmacological inhibition of cyclooxygenase-2 has been proven to reduce N-
methyl-D-aspartate-mediated neuronal cell death both in vitro [7] and in vivo [9]. Recent 
investigations have found a potentiation of excitotoxicity in transgenic mice overexpressing neuronal 
cyclooxygenase-2 [10] and a significant reduction in ischemic brain injury in cyclooxygenase-2-
deficient mice [9]. 
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Another mechanism by which cyclooxygenase-2 could contribute to cell death is related to induction 
of apoptosis. It was found in a previous report that the induction of cyclooxygenase-2 mRNA 
expression preceded temporally and overlapped anatomically the cellular morphological features of 
apoptosis in the granule cell layer of the dentate gyrus after hippocampal colchicine injection in rats 
and cyclooxygenase-2 induction preceded apoptosis in response to serum deprivation in P19 cells [8]. 
These findings suggest that cyclooxygenase-2 is involved in programmed cell death after brain injury.  
 
Additional experiments are needed to define the relative contribution of the above-mentioned 
pathogenic events to ischemic cell death related to cyclooxygenase-2 upregulation.  
 
In summary, this study demonstrates that the cyclooxygenase-2 inhibitor DFU has a neuroprotective 
effect against hippocampal neuronal damage in gerbils with a wide therapeutic window. This may 
indicate a potential use for cyclooxygenase-2 inhibitors as a valuable therapeutic strategy against 
cerebral ischemia to target the delayed progression of the damage.  
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Table 1 
Effects of the highly selective cyclooxygenase-2 inhibitor DFU (10 mg/kg, p.o.) on the spontaneous 
locomotor activity of groups of gerbils. Locomotor activity was measured prior to, and 7 days after 5-
min ischemia.  
 Number of movements/30 min/animal 
Groups Preischemic values 7 days after ischemia 
Sham (n=5) 54 ± 12 a  22 ± 9 a 
Vehicle (n=7) 52 ± 8 a 116 ± 26 b 
DFU pretreatment (n=6) 60 ± 10 a 80 ± 13 c 
DFU after 6 hr (n=9) 59 ± 19 a 71 ± 18 c 
DFU after 12 hr (n=9) 55 ± 10 a 79 ± 17 c 
Data are presented as mean ± SD. Values with non-identical superscript are significantly different 
(p<0.05) within the same set. ANOVA followed by Student-Newman-Keuls test. 
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Fig. 1. Effect of the selective cyclooxygenase-2 inhibitor DFU (10 mg/kg, p.o.) on the 
number of surviving cells in the hippocampal CA1 region 7 days after global ischemia in 
gerbils. Values are mean counts of normal-appearing CA1 neurons ± SD. *P<0.05 for the 
comparison between DFU-treated and vehicle-treated groups. **P<0.01 with respect to 
sham and DFU-treated groups. ANOVA followed by Student-Newman-Keuls post-hoc test. 
When DFU treatment is delayed until 6 h after ischemia, the neuroprotection is comparable 
to DFU-pretreated gerbils. Sham, sham-operated (n=5); Veh, vehicle-treated (n=7); DFU 
before, DFU administration starting 30 min before ischemia (n=6); DFU 6 h, DFU 
treatment started 6 h after ischemia (n=9); DFU 12 h, DFU administration was delayed 
until 12 h after ischemia (n=9); n.s., not significant. 
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